Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Waters

Showing results (61-70 of 134) with videos related to

Pageof 14
Sort By:
Journal of Virus Eradication|November 23, 2019
Highlights of the 10th International AIDS Society (IAS) Conference on HIV Science, 21-25 July 2019, Mexico City, MexicoChristina K Psomas, Laura Waters, Tristan Barber, et al.
The Journal of Antimicrobial Chemotherapy|March 31, 2009
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteersLaura Dickinson, Marta Boffito, David Back, et al.
Antiviral Therapy|May 9, 2013
Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backboneLaura Waters, Loveleen Bansi, David Asboe, et al.
Antiviral Therapy|June 26, 2014
Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapyLaura Waters, Akil Jackson, Laura Else, et al.
Clinical Medicine (London, England)|November 17, 2020
<i>Pneumocystis</i> pneumonia, a COVID-19 mimic, reminds us of the importance of HIV testing in COVID-19Sophie Kelly, Laura Waters, Muge Cevik, et al.
International Journal of Radiation Oncology, Biology, Physics|November 13, 2018
A Nomogram for Testosterone Recovery After Combined Androgen Deprivation and Radiation Therapy for Prostate CancerDaphna Y Spiegel, Julian C Hong, Taofik Oyekunle, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 22, 2009
Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteersMarta Boffito, Akil Jackson, Mohammed Lamorde, et al.
AIDS (London, England)|November 25, 2010
A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirineLaura Waters, Martin Fisher, Alan Winston, et al.
Journal of Pharmaceutical Analysis|March 4, 2020
Thermodynamics of clay-drug complex dispersions: Isothermal titration calorimetry and high-performance liquid chromatographyAna-Maria Totea, Juan Sabin, Irina Dorin, et al.
HIV Medicine|December 6, 2021
Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravirLucy Campbell, Fowzia Ibrahim, Birgit Barbini, et al.
Pageof 14

Showing results (61-70 of 134) with videos related to

Sort By:
Pageof 14
Journal of Virus Eradication|November 23, 2019
Highlights of the 10th International AIDS Society (IAS) Conference on HIV Science, 21-25 July 2019, Mexico City, MexicoChristina K Psomas, Laura Waters, Tristan Barber, et al.
The Journal of Antimicrobial Chemotherapy|March 31, 2009
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteersLaura Dickinson, Marta Boffito, David Back, et al.
Antiviral Therapy|May 9, 2013
Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backboneLaura Waters, Loveleen Bansi, David Asboe, et al.
Antiviral Therapy|June 26, 2014
Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapyLaura Waters, Akil Jackson, Laura Else, et al.
Clinical Medicine (London, England)|November 17, 2020
<i>Pneumocystis</i> pneumonia, a COVID-19 mimic, reminds us of the importance of HIV testing in COVID-19Sophie Kelly, Laura Waters, Muge Cevik, et al.
International Journal of Radiation Oncology, Biology, Physics|November 13, 2018
A Nomogram for Testosterone Recovery After Combined Androgen Deprivation and Radiation Therapy for Prostate CancerDaphna Y Spiegel, Julian C Hong, Taofik Oyekunle, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 22, 2009
Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteersMarta Boffito, Akil Jackson, Mohammed Lamorde, et al.
AIDS (London, England)|November 25, 2010
A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirineLaura Waters, Martin Fisher, Alan Winston, et al.
Journal of Pharmaceutical Analysis|March 4, 2020
Thermodynamics of clay-drug complex dispersions: Isothermal titration calorimetry and high-performance liquid chromatographyAna-Maria Totea, Juan Sabin, Irina Dorin, et al.
HIV Medicine|December 6, 2021
Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravirLucy Campbell, Fowzia Ibrahim, Birgit Barbini, et al.
Pageof 14